CELLIN

CELL INTELLIGENCE · 肿瘤细胞治疗研究

CELL INTELLIGENCE 肿瘤细胞治疗研究

← 返回前沿论文

生成用于治疗肾细胞癌的人干细胞来源 CD70 靶向同种异体 CAR-NKT 细胞的方案

英文原题：Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma.

查看英文原题

Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma.

PubMed 2026/01/13（内容时间） STAR Protoc Q4 · IF 1.4（JCR 2025）
靶点：CD70技术：NK 细胞肾细胞癌地区：美国
登录后收藏与关注 全文解读登录并开通会员后使用加入对比登录并开通会员后使用

研究概要

CD70已成为肾细胞癌（RCC）中一个有前景的免疫治疗靶点，针对CD70的单克隆抗体和嵌合抗原受体（CAR）疗法目前均在开发中。

中文摘要

CD70已成为肾细胞癌（RCC）中有前景的免疫治疗靶点，针对CD70的单克隆抗体和嵌合抗原受体（CAR）疗法目前均在开发中。在此，我们描述了一种利用临床导向培养从脐带血CD34+造血干/祖细胞（HSPC）生成人CD70靶向同种异体CAR-自然杀伤T（NKT）（Allo CAR70-NKT）细胞的方案。此外，我们描述了Allo CAR70-NKT细胞在体外介导针对RCC细胞系细胞毒性活性的治疗效果。关于本方案使用和执行的完整细节，请参阅Li等人1。

展开英文摘要原文

CD70 has emerged as a promising immunotherapeutic target in renal cell carcinoma (RCC), with both CD70-directed monoclonal antibodies and chimeric antigen receptor (CAR)-based therapies currently under development. Here, we describe a protocol for the generation of human CD70-directed allogeneic CAR-natural killer T (NKT) ( Allo CAR70-NKT) cells derived from cord blood CD34 + hematopoietic stem and progenitor cells (HSPCs) using a clinically guided culture. Furthermore, we describe the therapeutic efficacy of Allo CAR70-NKT cells in mediating cytotoxic activity against RCC cell lines in vitro. For complete details on the use and execution of this protocol, please refer to Li et al. 1 .

论文信息

作者
Li YR、Yang L
第一作者单位
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Bioengineering, UCLA, Los Angeles, CA 90095, USA. Electronic address: charlie.li@ucla.edu.United States
通讯作者单位
Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles (UCLA), Los Angeles, CA 90095, USA; Department of Bioengineering, UCLA, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA; Molecular Biology Institute, UCLA, Los Angeles, CA 90095, USA; Parker Institute for Cancer Immunotherapy, UCLA, Los Angeles, CA 90095, USA; Goodman-Luskin Microbiome Center, UCLA, Los Angeles, CA 90095, USA. Electronic address: liliyang@ucla.edu.United States
期刊
STAR protocols2026 Mar 20
原文标识
PubMed 41533507　·　DOI 10.1016/j.xpro.2025.104340

在 PubMed 查看 → 出版商原文（DOI） 报告译文或资料问题 →